219 related articles for article (PubMed ID: 15897740)
1. Columnar cell lesions of the breast: the missing link in breast cancer progression? A morphological and molecular analysis.
Simpson PT; Gale T; Reis-Filho JS; Jones C; Parry S; Sloane JP; Hanby A; Pinder SE; Lee AH; Humphreys S; Ellis IO; Lakhani SR
Am J Surg Pathol; 2005 Jun; 29(6):734-46. PubMed ID: 15897740
[TBL] [Abstract][Full Text] [Related]
2. High frequency of coexistence of columnar cell lesions, lobular neoplasia, and low grade ductal carcinoma in situ with invasive tubular carcinoma and invasive lobular carcinoma.
Abdel-Fatah TM; Powe DG; Hodi Z; Lee AH; Reis-Filho JS; Ellis IO
Am J Surg Pathol; 2007 Mar; 31(3):417-26. PubMed ID: 17325484
[TBL] [Abstract][Full Text] [Related]
3. Dimorphic cells: a common feature throughout the low nuclear grade breast neoplasia spectrum.
de Boer M; van Diest PJ
Virchows Arch; 2023 Feb; 482(2):369-375. PubMed ID: 36378325
[TBL] [Abstract][Full Text] [Related]
4. Morphologic and molecular evolutionary pathways of low nuclear grade invasive breast cancers and their putative precursor lesions: further evidence to support the concept of low nuclear grade breast neoplasia family.
Abdel-Fatah TM; Powe DG; Hodi Z; Reis-Filho JS; Lee AH; Ellis IO
Am J Surg Pathol; 2008 Apr; 32(4):513-23. PubMed ID: 18223478
[TBL] [Abstract][Full Text] [Related]
5. Estrogen Receptor and Cytokeratin 5 Are Reliable Markers to Separate Usual Ductal Hyperplasia From Atypical Ductal Hyperplasia and Low-Grade Ductal Carcinoma In Situ.
Martinez AP; Cohen C; Hanley KZ; Li XB
Arch Pathol Lab Med; 2016 Jul; 140(7):686-9. PubMed ID: 27116088
[TBL] [Abstract][Full Text] [Related]
6. [Value of CK5/6, CK14, ER and PR detection in differential diagnosis of intraductal proliferative lesions of the breast].
Niu F; Wang L; Zhang W; Lyu S; Niu Y
Zhonghua Zhong Liu Za Zhi; 2015 Oct; 37(10):749-52. PubMed ID: 26813593
[TBL] [Abstract][Full Text] [Related]
7. Papillomatous breast lesions with atypical columnar cell features.
de Boer M; Verschuur-Maes AHJ; Moelans C; van Diest PJ
J Clin Pathol; 2023 Apr; 76(4):228-233. PubMed ID: 36693714
[TBL] [Abstract][Full Text] [Related]
8. Molecular alterations in columnar cell lesions of the breast.
Dabbs DJ; Carter G; Fudge M; Peng Y; Swalsky P; Finkelstein S
Mod Pathol; 2006 Mar; 19(3):344-9. PubMed ID: 16400324
[TBL] [Abstract][Full Text] [Related]
9. Proliferative epithelial changes in tumour adjacent tissue in Sri Lankan women with breast carcinoma: do morphological changes support molecular models of breast carcinogenesis?
Jinadasa IM; Wijesinghe HD; Jayawickrama MMA; Lokuhetty MDS
Diagn Pathol; 2022 Dec; 17(1):97. PubMed ID: 36581929
[TBL] [Abstract][Full Text] [Related]
10. CD133 expressionand clinicopathologic significance in benign and malignant breast lesions.
Liu TT; Li XF; Wang L; Yang JL
Cancer Biomark; 2020; 28(3):293-299. PubMed ID: 32390595
[TBL] [Abstract][Full Text] [Related]
11. Progression risk of columnar cell lesions of the breast diagnosed in core needle biopsies.
Verschuur-Maes AH; Witkamp AJ; de Bruin PC; van der Wall E; van Diest PJ
Int J Cancer; 2011 Dec; 129(11):2674-80. PubMed ID: 21225627
[TBL] [Abstract][Full Text] [Related]
12. Precursor Lesions of the Low-Grade Breast Neoplasia Pathway.
Collins LC
Surg Pathol Clin; 2018 Mar; 11(1):177-197. PubMed ID: 29413656
[TBL] [Abstract][Full Text] [Related]
13. The mucinous variant of columnar cell lesions.
Verschuur-Maes AH; Van Diest PJ
Histopathology; 2011 May; 58(6):847-53. PubMed ID: 21585423
[TBL] [Abstract][Full Text] [Related]
14. Identifying a highly-aggressive DCIS subgroup by studying intra-individual DCIS heterogeneity among invasive breast cancer patients.
Pape-Zambito D; Jiang Z; Wu H; Devarajan K; Slater CM; Cai KQ; Patchefsky A; Daly MB; Chen X
PLoS One; 2014; 9(6):e100488. PubMed ID: 24978026
[TBL] [Abstract][Full Text] [Related]
15. Alterations of ER, PR, HER-2/neu, and P53 protein expression in ductal breast carcinomas and clinical implications.
Liu C; Zhang H; Shuang C; Lu Y; Jin F; Xu H; Lu P
Med Oncol; 2010 Sep; 27(3):747-52. PubMed ID: 19657752
[TBL] [Abstract][Full Text] [Related]
16. Possible Prognostic Role of HER2/Neu in Ductal Carcinoma In Situ and Atypical Ductal Proliferative Lesions of the Breast.
Daoud SA; Ismail WM; Abdelhamid MS; Nabil TM; Daoud SA
Asian Pac J Cancer Prev; 2016; 17(8):3733-6. PubMed ID: 27644608
[TBL] [Abstract][Full Text] [Related]
17. Atypia in breast pathology: what pathologists need to know.
Katayama A; Toss MS; Parkin M; Ellis IO; Quinn C; Rakha EA
Pathology; 2022 Feb; 54(1):20-31. PubMed ID: 34872753
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic progression of columnar cell lesions of the breast to invasive breast cancer.
Verschuur-Maes AH; de Bruin PC; van Diest PJ
Breast Cancer Res Treat; 2012 Dec; 136(3):705-15. PubMed ID: 23104224
[TBL] [Abstract][Full Text] [Related]
19. Impact of immunohistochemical markers, CK5/6 and E-cadherin on diagnostic agreement in non-invasive proliferative breast lesions.
MacGrogan G; Arnould L; de Mascarel I; Vincent-Salomon A; Penault-Llorca F; Lacroix-Triki M; Bibeau F; Baranzelli MC; Fridman V; Antoine M; Bécette V; Brouste V; Jacquemier J; Mathoulin-Pélissier S;
Histopathology; 2008 May; 52(6):689-97. PubMed ID: 18397281
[TBL] [Abstract][Full Text] [Related]
20. Inter-observer variability between general pathologists and a specialist in breast pathology in the diagnosis of lobular neoplasia, columnar cell lesions, atypical ductal hyperplasia and ductal carcinoma in situ of the breast.
Gomes DS; Porto SS; Balabram D; Gobbi H
Diagn Pathol; 2014 Jun; 9():121. PubMed ID: 24948027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
